Cart
sales@molnova.com
Methyl 13-cis-4-Oxoretinoate
CAS No. 71748-57-7
Methyl 13-cis-4-Oxoretinoate( Methyl 13-cis-4-Oxoretinoate )
Catalog No. M19030 CAS No. 71748-57-7
4-Keto 13-cis-Retinoic Acid is a retinoic acid metabolite in neuroblastoma.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 157 | In Stock |
|
| 2MG | 88 | In Stock |
|
| 5MG | 161 | In Stock |
|
| 10MG | 237 | In Stock |
|
| 25MG | 427 | In Stock |
|
| 50MG | 613 | In Stock |
|
| 100MG | 873 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1748 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMethyl 13-cis-4-Oxoretinoate
-
NoteResearch use only, not for human use.
-
Brief Description4-Keto 13-cis-Retinoic Acid is a retinoic acid metabolite in neuroblastoma.
-
DescriptionMethyl 13-cis-4-Oxoretinoate is a bioactive chemical.
-
In Vitro——
-
In Vivo——
-
SynonymsMethyl 13-cis-4-Oxoretinoate
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number71748-57-7
-
Formula Weight314.42
-
Molecular FormulaC20H26O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC1=C(C(CCC1=O)(C)C)/C=C/C(=C/C=C/C(=C\C(=O)OC)/C)/C
-
Chemical NameMethyl (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-3-oxocyclohexen-1-yl)nona-2,4,6,8-tetraenoate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Selaginellin
Selaginellin has a neuroprotective effect against L-glutamate-induced neurotoxicity through mechanisms related to anti-oxidation and anti-apoptosis via scavenging reactive oxygen species and up-regulating the expression of klotho gene.
-
AB-680
AB-680 is a highly potent, reversible, and selective inhibitor of CD73 (an ectonucleotidase, Ki: 4.9 pM for hCD73) with anti-tumor activity.
-
PACAP (1-38), human,...
PACAP (1-38), a novel neuropeptide isolated from the bovine hypothalamus is more active than vasoactive intestinal peptide (VIP) in stimulating adenylate cyclase (EC50=7 nM). PACAP 1-38 (10-9 M) increased substance P (SP), gastrin releasing peptide (GRP), and VIP release. PACAP 1-38 (10-8 M) inhibited gastrin secretion and stimulated somatostatin secretion and motility dose-dependently.
